The Community Outreach group at Cleveland Clinic’s Taussig Cancer Center sought input from people at local faith-based organizations to better understand and address the history of health disparities in the community.
The phase 3 KEYNOTE-630 trial has begun enrolling patients with high-risk, locally advanced cutaneous squamous cell carcinoma (cSCC) to evaluate the curative potential of PD-1 inhibitor pembrolizumab.
Pembrolizumab plus axitinib is another effective option for treating renal cell carcinoma, indicates the KEYNOTE-426 study.
In high-risk resected oral cavity squamous cell carcinoma, median disease-free survival doubles when patients receive 200 mg/m2 or more of cisplatin along with radiation therapy, shows one study.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
See these presentations by Cleveland Clinic Cancer Center staff at ASCO 2019.
With time to treat rising nationally, Cleveland Clinic is seeing reductions. How? Get the answer from Digestive Disease & Surgery Institute Chairman Conor Delaney, MD, PhD, in our “The Short Answer” series.
Top 10 favorite abstracts from ASCO 2016, chosen by Cleveland Clinic’s Hematologists and Medical Oncologists
Breast cancer survivors treated with chemotherapy were much more likely to experience long-term symptoms than those who did not receive chemotherapy, a Cleveland Clinic analysis finds.
Analysis finds tumor PD-L1 expression with a 5 percent cutoff is a reliable predictor of treatment success with PD-1/PD-L1 checkpoint inhibitors in the treatment of lung and other hard-to-treat cancers.
The diagnosis and treatment of pancreatic cancer remains challenging, with no screening programs and relatively little progress in improving survival rates. In an effort to standardize care and address knowledge gaps, the American Society of Clinical Oncology has issued new treatment guidelines for potentially curable, locally advanced and metastatic pancreatic cancer. Cleveland Clinic Cancer Center oncologists helped lead the effort.